Recently, scientists from the Beijing Institute of Genomics of the Chinese Academy of Sciences (China National Center for Bioinformation) and Department of Urology, Peking University First Hospital, reported the epigenomic features and profiles of UTUC and UCB, identified DNA methylation subtypes with potential risk stratification of tumors, and evaluated therapeutic efficacy and targets of the DNA methyltransferase inhibitor SGI-110.
This study, published online in BMC Medicine, highlights similar management approaches for UC, and a roadmap for clinical practice: DNA methylation subtype classification may be used to predict the outcome of resected UC patients.
Utilizing the whole-genome bisulfite sequencing method, scientists discovered that UTUC and UCB have virtually identical DNA methylation profiles, plus they characterized potential links between DNA methylation and clinical outcomes.
DNA methylation classification identified two epi-clusters, Methy-High and Methy-Low, Methy-High tumors were hypermethylated, immune-infiltrated, and enriched for exhausted T cells, with poor clinical outcome. DNA methyltransferase inhibitor SGI-110 inhibited the migration and invasion of Methy-High UC cell lines by upregulating multiple antitumor immune pathways.
The analysis demonstrated the critical role of DNA methylation subtypes for predicting patient prognosis in UC, providing mechanistic rationale for evaluating SGI-110 in treating UC patients in the clinic.
More info: Juan Li et al, DNA methylation subtypes guiding prognostic assessment and linking to responses the DNA methyltransferase inhibitor SGI-110 in urothelial carcinoma, BMC Medicine (2022). DOI: 10.1186/s12916-022-02426-w
Citation: DNA methylation subtype classification can predict outcomes of urothelial carcinoma (2022, July 26) retrieved 26 July 2022 from https://medicalxpress.com/news/2022-07-dna-methylation-subtype-classification-outcomes.html
This document is at the mercy of copyright. Aside from any fair dealing for the intended purpose of private study or research, no part could be reproduced minus the written permission. This content is provided for information purposes only.